|
1
|
Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol. 172:910–914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang SS: Treatment options for hormone-refractory prostate cancer. Rev Urol. 9 (Suppl 2):S13–S18. 2007.PubMed/NCBI
|
|
4
|
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 9:401–406. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499–4506. 2002.PubMed/NCBI
|
|
6
|
Jernberg E, Bergh A and Wikstrom P: Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect. 6:R146–R161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G, Berney DM, Foster CS, et al: Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer. 110:1655–1662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, et al: Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 488:337–342. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bergmann C, Zerres K, Senderek J, Rudnik-Schoneborn S, Eggermann T, Häusler M, Mull M and Ramaekers VT: Oligophrenin 1 (OPHN1) gene mutation causes syndromic X-linked mental retardation with epilepsy, rostral ventricular enlargement and cerebellar hypoplasia. Brain. 126:1537–1544. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al-Owain M, Kaya N, Al-Zaidan H, Al-Hashmi N, Al-Bakheet A, Al-Muhaizea M, Chedrawi A, Basran RK and Milunsky A: Novel intragenic deletion in OPHN1 in a family causing XLMR with cerebellar hypoplasia and distinctive facial appearance. Clin Genet. 79:363–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Busa T, Caietta E, Chabrol B, Girard N, Philip N and Missirian C: Large in-frame intragenic deletion of OPHN1 in a male patient with a normal intelligence quotient score. Clin Dysmorphol. 26:47–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goto K, Oue N, Hayashi T, Shinmei S, Sakamoto N, Sentani K, Teishima J, Matsubara A and Yasui W: Oligophrenin-1 is associated with cell adhesion and migration in prostate cancer. Pathobiology. 81:190–198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L and Kohli M: Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 23:705–713. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, et al: Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 116:11428–11436. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, Kim CJ, Carbone EA, Vasselman SE, Nguyen B, et al: Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin Cancer Res. 26:3230–3238. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hodgson MC, Astapova I, Hollenberg AN and Balk SP: Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 67:8388–8395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M and Miyamoto M: Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63:149–153. 2003.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kilkenny C, Browne W, Cuthill IC, Emerson M and Altman DG; NC3Rs Reporting Guidelines Working Group, : Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol. 160:1577–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T and Aoki Y: Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate. 70:745–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Albertson DG: Gene amplification in cancer. Trends Genet. 22:447–455. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML and Kallioniemi A: Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA. 98:5711–5716. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M and Corless CL: Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn. 17:53–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, Servant N, Gestraud P, Rio Frio T, et al: Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 30:3443–3450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, et al: HER2 Status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib. Mol Cancer Ther. 16:228–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bivin WW, Yergiyev O, Bunker ML, Silverman JF and Krishnamurti U: GRB7 expression and correlation with HER2 amplification in invasive breast carcinoma. Appl Immunohistochem Mol Morphol. 25:553–558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Doi A, Ishikawa K, Shibata N, Ito E, Fujimoto J, Yamamoto M, Shiga H, Mochizuki H, Kawamura Y, Goshima N, et al: Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures. Mol Oncol. 9:355–364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katoh M and Katoh M: MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. Int J Oncol. 22:1369–1374. 2003.PubMed/NCBI
|
|
32
|
Glynn RW, Miller N and Kerin MJ: 17q12-21-the pursuit of targeted therapy in breast cancer. Cancer Treat Rev. 36:224–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsui A, Ihara T, Suda H, Mikami H and Semba K: Gene amplification: Mechanisms and involvement in cancer. Biomol Concepts. 4:567–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Waltering KK, Urbanucci A and Visakorpi T: Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol. 360:38–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Karantanos T, Corn PG and Thompson TC: Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng Q and He B: Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol. 9:8582019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
38
|
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 6:703–706. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M and Scagliotti GV: Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 41:884–892. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA. 107:16759–16765. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Edwards J, Krishna NS, Grigor KM and Bartlett JM: Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 89:552–556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang X, Hong SZ, Lin EJ, Wang DY, Li ZJ and Chen LI: Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis. Oncol Lett. 9:2617–2622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Du M, Huang CC, Tan W, Kohli M and Wang L: Multiplex digital PCR to detect amplifications of specific androgen receptor loci in cell-free DNA for prognosis of metastatic castration-resistant prostate cancer. Cancers (Basel). 12:21392020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dicken BJ, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S and Cass C: Lymphovascular invasion is associated with poor survival in gastric cancer: An application of gene-expression and tissue array techniques. Ann Surg. 243:64–73. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Cheng H, Pan T, Liu Y, Su Y, Ren C, Huang D, Zha X and Liang C: mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. Mol Carcinog. 54:1086–1095. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen W, Delongchamps NB, Mao K, Beuvon F, Peyromaure M, Liu Z and Dinh-Xuan AT: High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett. 11:1375–1381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu J, Wang L, Zhang Y, Li S, Sun F, Wang G, Yang T, Wei D, Guo L and Xiao H: Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications. Oncol Lett. 17:3151–3162. 2019.PubMed/NCBI
|
|
48
|
Ahmat Amin MKB, Shimizu A, Zankov DP, Sato A, Kurita S, Ito M, Maeda T, Yoshida T, Sakaue T, Higashiyama S, et al: Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene. 37:5416–5434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zins K, Lucas T, Reichl P, Abraham D and Aharinejad S: A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 8:e749242013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, et al: Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. Mol Endocrinol. 24:722–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA and Burnstein KL: Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol. 22:597–608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y and Feng F: Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. Oncol Lett. 20:2997–3005. 2020. View Article : Google Scholar : PubMed/NCBI
|
